Theravance Biopharma Inc. and Mylan Reach Settlement with Eugia Over YUPELRI® Patent Dispute, Allowing Generic Launch in 2039

Reuters

06 Jun

<a href="https://laohu8.com/S/TBPH">Theravance Biopharma Inc.</a> and Mylan Reach Settlement with Eugia Over YUPELRI® Patent Dispute, Allowing Generic Launch in 2039

Theravance Biopharma has reached a settlement agreement with Eugia Pharma Specialities Ltd. and its affiliates regarding ongoing patent litigation over the drug YUPELRI® (revefenacin) inhalation solution. The settlement, which resolves disputes under the Hatch-Waxman Act, grants Eugia a royalty-free, non-exclusive license to manufacture and market a generic version of the drug in the U.S. from April 23, 2039. This agreement is pending review by the U.S. Department of Justice and the Federal Trade Commission. Patent litigation with other ANDA filers, Cipla Limited and Mankind Pharma Ltd., remains ongoing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theravance Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-056996), on June 06, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2541855726"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2541855726\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2541855726?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-06 18:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2541855726","market":"us","top_or_hot":-1,"title":"Theravance Biopharma Inc. and Mylan Reach Settlement with Eugia Over YUPELRI® Patent Dispute, Allowing Generic Launch in 2039","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TBPH\">Theravance Biopharma Inc.</a> and Mylan Reach Settlement with Eugia Over YUPELRI® Patent Dispute, Allowing Generic Launch in 2039\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Theravance Biopharma has reached a settlement agreement with Eugia Pharma Specialities Ltd. and its affiliates regarding ongoing patent litigation over the drug YUPELRI® (revefenacin) inhalation solution. The settlement, which resolves disputes under the Hatch-Waxman Act, grants Eugia a royalty-free, non-exclusive license to manufacture and market a generic version of the drug in the U.S. from April 23, 2039. This agreement is pending review by the U.S. Department of Justice and the Federal Trade Commission. Patent litigation with other ANDA filers, Cipla Limited and Mankind Pharma Ltd., remains ongoing.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theravance Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-056996), on June 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Theravance Biopharma Inc. and Mylan Reach Settlement with Eugia Over YUPELRI® Patent Dispute, Allowing Generic Launch in 2039</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTheravance Biopharma Inc. and Mylan Reach Settlement with Eugia Over YUPELRI® Patent Dispute, Allowing Generic Launch in 2039\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-06 18:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TBPH\">Theravance Biopharma Inc.</a> and Mylan Reach Settlement with Eugia Over YUPELRI® Patent Dispute, Allowing Generic Launch in 2039\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Theravance Biopharma has reached a settlement agreement with Eugia Pharma Specialities Ltd. and its affiliates regarding ongoing patent litigation over the drug YUPELRI® (revefenacin) inhalation solution. The settlement, which resolves disputes under the Hatch-Waxman Act, grants Eugia a royalty-free, non-exclusive license to manufacture and market a generic version of the drug in the U.S. from April 23, 2039. This agreement is pending review by the U.S. Department of Justice and the Federal Trade Commission. Patent litigation with other ANDA filers, Cipla Limited and Mankind Pharma Ltd., remains ongoing.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theravance Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-056996), on June 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nNDL3Ffm98:1","article_id":"2541855726","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2541855726","pubTimestamp":1749204227,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Theravance Biopharma has reached a settlement agreement with Eugia Pharma Specialities Ltd. and its affiliates regarding ongoing patent litigation over the drug YUPELRI  inhalation solution. The settlement, which resolves disputes under the Hatch-Waxman Act, grants Eugia a royalty-free, non-exclusive license to manufacture and market a generic version of the drug in the U.S. from April 23, 2039. This agreement is pending review by the U.S. Department of Justice and the Federal Trade Commission. Patent litigation with other ANDA filers, Cipla Limited and Mankind Pharma Ltd., remains ongoing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theravance Biopharma Inc. published the original content used to generate this news brief via EDGAR,","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Theravance Biopharma Inc.和Mylan就YUPELRI®专利纠纷与Eugia达成和解，允许仿制药于2039年上市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TBPH":0.9},"content_text":"Theravance Biopharma Inc. and Mylan Reach Settlement with Eugia Over YUPELRI® Patent Dispute, Allowing Generic Launch in 2039\n    \n\n        Theravance Biopharma has reached a settlement agreement with Eugia Pharma Specialities Ltd. and its affiliates regarding ongoing patent litigation over the drug YUPELRI® (revefenacin) inhalation solution. The settlement, which resolves disputes under the Hatch-Waxman Act, grants Eugia a royalty-free, non-exclusive license to manufacture and market a generic version of the drug in the U.S. from April 23, 2039. This agreement is pending review by the U.S. Department of Justice and the Federal Trade Commission. Patent litigation with other ANDA filers, Cipla Limited and Mankind Pharma Ltd., remains ongoing.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theravance Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-056996), on June 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}